Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 10, 2025
DataAggregated Company Financials
Companies563
- 7D-9.0%
- 3M-13.1%
- 1Y-15.2%
- YTD-10.4%
Over the last 7 days, the Biotech industry has dropped 9.0%, driven by AbbVie declining 7.0%. In contrast, Neurocrine Biosciences has gained 5.5%. However, the industry is down 15% over the past year. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 10 May 2025 | US$879.4b | US$154.9b | -US$24,542,496,165.11 | 16.7x | -35.8x | 5.7x |
| Mon, 07 Apr 2025 | US$735.9b | US$118.6b | -US$37,018,260,571.73 | 20.1x | -19.9x | 6.2x |
| Wed, 05 Mar 2025 | US$831.7b | US$119.0b | -US$37,123,415,733.90 | 16.4x | -22.4x | 7x |
| Fri, 31 Jan 2025 | US$990.2b | US$149.5b | -US$26,311,030,486.43 | 17.4x | -37.6x | 6.6x |
| Sun, 29 Dec 2024 | US$977.8b | US$149.9b | -US$26,372,711,577.30 | 16.2x | -37.1x | 6.5x |
| Tue, 26 Nov 2024 | US$1.0t | US$150.0b | -US$26,579,608,946.27 | 16.4x | -38.2x | 6.8x |
| Thu, 24 Oct 2024 | US$897.0b | US$113.1b | -US$36,020,164,121.55 | 21x | -24.9x | 7.9x |
| Sat, 21 Sep 2024 | US$927.5b | US$113.2b | -US$35,987,032,000.31 | 21.9x | -25.8x | 8.2x |
| Mon, 19 Aug 2024 | US$883.2b | US$113.2b | -US$35,819,260,655.83 | 22.3x | -24.7x | 7.8x |
| Wed, 17 Jul 2024 | US$1.2t | US$164.5b | -US$28,050,454,935.07 | 29.4x | -42.6x | 7.3x |
| Fri, 14 Jun 2024 | US$1.2t | US$164.5b | -US$28,081,541,373.98 | 27.8x | -41.3x | 7.1x |
| Sun, 12 May 2024 | US$1.1t | US$164.6b | -US$26,967,551,943.98 | 23.3x | -41.2x | 6.7x |
| Tue, 09 Apr 2024 | US$1.1t | US$164.4b | -US$23,377,181,270.88 | 21x | -48.3x | 6.9x |
| Thu, 07 Mar 2024 | US$1.2t | US$167.9b | -US$21,278,119,441.95 | 16x | -55.9x | 7.1x |
| Sat, 03 Feb 2024 | US$1.4t | US$203.9b | -US$24,418,168,728.00 | 19.2x | -58.9x | 7.1x |
| Mon, 01 Jan 2024 | US$1.4t | US$204.9b | -US$22,199,078,413.00 | 19.8x | -62.6x | 6.8x |
| Wed, 29 Nov 2023 | US$1.2t | US$204.8b | -US$22,005,071,481.00 | 17.8x | -55.6x | 6x |
| Fri, 27 Oct 2023 | US$1.2t | US$207.5b | -US$12,993,510,910.00 | 16.8x | -93.2x | 5.8x |
| Sun, 24 Sep 2023 | US$1.3t | US$207.5b | -US$12,879,333,723.00 | 17.1x | -97.9x | 6.1x |
| Tue, 22 Aug 2023 | US$1.3t | US$207.6b | -US$12,363,308,148.00 | 17.5x | -102.3x | 6.1x |
| Thu, 20 Jul 2023 | US$1.1t | US$186.6b | -US$15,972,272,220.00 | 12.8x | -71.5x | 6.1x |
| Sat, 17 Jun 2023 | US$1.2t | US$186.3b | -US$16,045,332,946.00 | 12.1x | -72.3x | 6.2x |
| Mon, 15 May 2023 | US$1.2t | US$191.7b | -US$12,222,188,637.00 | 13.8x | -94.5x | 6x |
| Wed, 12 Apr 2023 | US$1.2t | US$198.3b | -US$3,303,389,351.00 | 13.9x | -351.9x | 5.9x |
| Fri, 10 Mar 2023 | US$1.1t | US$199.1b | -US$4,987,732,730.00 | 15x | -221x | 5.5x |
| Sun, 05 Feb 2023 | US$1.2t | US$203.6b | US$1.6b | 15.6x | 711.4x | 5.7x |
| Tue, 03 Jan 2023 | US$1.2t | US$203.5b | US$1.7b | 14.3x | 667.4x | 5.7x |
| Thu, 01 Dec 2022 | US$1.2t | US$202.3b | US$1.3b | 15.1x | 918x | 5.7x |
| Sat, 29 Oct 2022 | US$1.1t | US$205.9b | US$7.4b | 14.3x | 148.7x | 5.3x |
| Mon, 26 Sep 2022 | US$1.0t | US$206.0b | US$5.6b | 13.9x | 182.3x | 4.9x |
| Wed, 24 Aug 2022 | US$1.1t | US$206.3b | US$7.3b | 15.8x | 146.5x | 5.2x |
| Fri, 22 Jul 2022 | US$1.1t | US$211.4b | US$11.3b | 16.6x | 95.9x | 5.1x |
| Sun, 19 Jun 2022 | US$952.2b | US$212.2b | US$10.9b | 14.8x | 87x | 4.5x |
| Tue, 17 May 2022 | US$995.0b | US$211.9b | US$10.6b | 16x | 93.6x | 4.7x |
Price to Earnings Ratio
93.6x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.9% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.30% | |
| Healthcare | -4.39% | |
| Biotech | -9.04% | |
| Biotech | -9.04% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | US$115.71 | 5.5% +US$599.8m | -15.4% | PE37.4x | |
| HALO Halozyme Therapeutics | US$65.87 | 7.6% +US$557.6m | 52.7% | PE16.7x | |
| ALVO Alvotech | US$9.68 | 17.8% +US$440.6m | -27.6% | PE30.3x | |
| ACAD ACADIA Pharmaceuticals | US$17.44 | 17.0% +US$422.0m | 14.4% | PE12.7x | |
| UTHR United Therapeutics | US$301.42 | 2.3% +US$307.6m | 14.1% | PE11.2x |
